Navigation Links
Applegate CEO Worries FDA Plan To Address Antibiotics In Animal Agriculture Is Too Little, Too Late
Date:12/12/2013

BRIDGEWATER, N.J., Dec. 12, 2013 /PRNewswire/ -- Stephen McDonnell, founder and CEO of Applegate, the leading producer of natural and organic meats and cheeses, today expressed concern regarding the Food and Drug Administration's (FDA) attempt to curb the overuse of antibiotics in food animal production.

"Before we do a victory dance to celebrate the FDA's 'crackdown' on antibiotic use, we need to take a closer look at what the agency is really doing," said McDonnell.  "The FDA is moving in the right direction by acknowledging that there is a problem, but it's not one we'll be able solve by relying on self-regulation and voluntary compliance. The industry has always had the opportunity to voluntarily stop using antibiotics. But instead, antibiotic use in animal agriculture has increased, despite warnings that this practice leads to antibiotic resistance in humans."

According to government reports, nearly 80 percent of the antibiotics sold in the U.S. go to animals raised for food.

The non-binding FDA guidance states that antibiotics should be used only when necessary to keep animals healthy and only under the supervision of a veterinarian. Additionally, the agency is requesting cooperation from drug manufacturers to remove non-therapeutic uses of antibiotics (such as growth promotion) from drug labels. Cooperation with the new recommendations is strictly voluntary, and the pharmaceutical and animal agriculture industries have three years to work within the voluntary measures before the FDA evaluates the efficacy of the plan.

"Under this guidance, antibiotics can still be used to prevent disease, which most likely means millions of pounds of antibiotics will go to animals to make up for crowded and unsanitary conditions in some industrial animal agriculture operations," says McDonnell. "Health experts are proclaiming that antibiotic resistance is the single biggest threat
'/>"/>

SOURCE Applegate
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
2. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
3. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
4. AUA Foundation Launches Campaign to Address Stigma of Overactive Bladder
5. ACEP Commends Congress For Passing Legislation That Addresses Drug Shortages As Well As "Bath Salts"
6. ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
7. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
8. Generex Addresses Recent Trading Volume in Shares of its Common Stock
9. Top FDA Official Stephen P. Spielberg, MD, PhD, to Deliver Plenary Address at 2012 ISPE Annual Meeting
10. Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
11. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SGP ), a leader in hepatitis research, ... III studies of boceprevir, its,investigational oral hepatitis C ... virus (HCV) genotype 1. One study,will be in ... patients,who failed prior treatment (relapsers and nonresponders), an ...
... Laboratories, L.C., a,privately-owned biopharmaceutical company, today announced the ... to evaluate the safety and,efficacy of nitazoxanide in ... with chronic hepatitis C genotype 1 who have ... therapy (peginterferon and,ribavirin). The company expects to announce ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... tools, but ,talking, computer program helped , , FRIDAY, ... the written questions American doctors have them answer ... question the usefulness of these screening tools, new ... year at the 2008 Clinical Congress of the ...
... WASHINGTON, Oct. 17 After a destructive,hurricane season that ... the American Public Health Association (APHA) wants to ensure,that ... storms and any other,potential emergencies you may face. With ... a new campaign aimed at encouraging Americans to,make sure ...
... AUBURN HILLS, Mich., Oct. 17 Chrysler LLC ... companies will bring an,innovative diabetes program to its ... developed with the Henry Ford Health System,and is ... and,care with existing workplace wellness initiatives. All employees ...
... into tobacco dependence published online today (Friday 17 October 2008) ... that recent ex-smokers who find exposure to other people,s cigarette ... those who find it unpleasant. , Led by Dr Hayden ... Unit at Barts and The London School of Medicine and ...
... ShotsTM Brings Public Health Message to Austin,s American,Heart ... Heart disease was the leading,cause of death ... in every,10 deaths. People with heart disease are ... complications from the flu. Therefore, the,U.S. Centers for ...
... break fundraising records for breast ... cancer research, SEATTLE, ... Breast Cancer Awareness month to raise money for breast,cancer research. This is ... to help breast cancer research and who has,not completed their will to ...
Cached Medicine News:Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:How Can Doing Your Will Online Help Cure Breast Cancer? 2
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... heart, the only therapy solution open to them is ... are not always readily available. For this reason, too ... list for a donor organ. , ,This is where ... a patient. On the one hand, these systems can ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay ... Advantage® Specialty System. The Nichols Advantage® 25-Hydroxyvitamin ... determination of 25-,hydroxyvitamin D (25-OH-D) and other ... or plasma to be used as an ...
Medicine Products: